Search clinical trials for: 852A

Total 32 results

Masonic Cancer Center, University of Minnesota
Pfizer

Terminated

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
Rogers, B.H. Gerald, M.D.
3M

Terminated

Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus

Barrett Esophagus

United States
Pfizer

Completed

Use of 852A in Metastatic Cutaneous Melanoma.

Melanoma | Unresectable Metatstatic Cutaneous Melanoma

Switzerland, Germany, France
Masonic Cancer Center, University of Minnesota
Pfizer

Completed

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

Neoplasms

United States
Pfizer

Completed

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

Melanoma

United States
Masonic Cancer Center, University of Minnesota
Pfizer

Completed

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Renal Impairment
National Institute on Drug Abuse (NIDA)

Completed

The Study of AZD8529 for Smoking Cessation in Female Smokers

Tobacco Use Disorder

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma

Asthma

United Kingdom
François Spertini
University of Oxford

Completed

ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039) (TB039)

Tuberculosis | Mycobacterium Tuberculosis, Protection Against

Switzerland
University of Oxford
University of Cape Town

Completed

Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town

Tuberculosis

South Africa
Merck Sharp & Dohme LLC

Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Human Immunodeficiency Virus | AIDS Virus

Romania
Merck Sharp & Dohme LLC

Completed

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Human Immunodeficiency Virus

Romania, South Africa
University of Oxford

Completed

Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.

Tuberculosis

United Kingdom
Cryonove Pharma
CEISO; Dermatech; INNOVSOLUTION

Completed

Tolerance of Cyto-selective Difluoroethane-based Cryotherapy (AGILE3)

Solar Lentigo

Ukraine
University of Oxford

Completed

Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route

Tuberculosis

United Kingdom
University of Oxford

Completed

A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG

Tuberculosis

United Kingdom
University of Oxford
University of Birmingham

Completed

Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults

Tuberculosis

United Kingdom
Chiesi Farmaceutici S.p.A.

Recruiting

Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) (TRECOS)

Asthma

United Kingdom
University of Oxford
MRC/UVRI and LSHTM Uganda Research Unit

Completed

Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (TB036)

Tuberculosis

Uganda
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Type II Diabetes Mellitus
TheRas, Inc

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

Mucociliary Clearance

United Kingdom
University of Oxford
Medical Research Council

Completed

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

TB

Gambia
University of Oxford
University of Cape Town

Completed

A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both

HIV Infections | TB

South Africa
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
AstraZeneca

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

Schizophrenia

United States
GlaxoSmithKline

Completed

Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants

Asthma

Netherlands
GlaxoSmithKline

Not yet recruiting

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma

Asthma

Argentina, United States, Canada, Panama, Greece, France, Poland, Italy, United Kingdom

3

Subscribe